Compare Nasdaq100 ETF (QQQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs GeneDx Holdings Corp — how do they compare? Nasdaq100 ETF trades at $751.27 (market cap $506.92B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Nasdaq100 ETF is far larger — about 251× GeneDx Holdings Corp's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and GeneDx Holdings Corp for 19 Days on average.
| QQQ | WGS | |
|---|---|---|
Market Cap | $506.92B | $2.02B |
Volume | 48,326,518 | 734,640 |
52-Week High | $759.66 | $167.51 |
52-Week Low | $558.34 | $34.51 |
Typical Hold Time | 162 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $747.64, down 1.33% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite mixed analyst sentiment. Recent news highlights QQQ's concentration in technology stocks and ongoing comparisons with lower-cost alternatives like VOO and QQQM.
The outlook remains positive given QQQ's exposure to leading tech innovators and AI-driven growth potential, though elevated valuations and interest rate sensitivity present near-term risks. Long-term growth prospects appear solid, but investors should monitor concentration risk and fee differentials among competing ETFs.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
